INS and Insulin resistance: Chronic rapamycin administration has been reported to cause whole-body insulin resistance by reducing mTORC2 in several insulin-sensitive tissues (e.g., liver, adipose tissue, and skeletal muscle) [12], suggesting that the effects of rapamycin administration and energy restriction on skeletal muscle are different, and rapamycin administration might negatively impact skeletal muscle and whole-body glucose metabolism.